GENENCOR RECEIVES DEFENSE CONTRACT TO DEVELOP A PROCESS FOR EMERGENCY PHARMACUETICAL MANUFACTURING

Genencor International, a Danisco company, announced today that it has received a grant from the U.S. Defense Advanced Research Projects Agency (DARPA) to develop a process for rapid manufacture of emergency pharmaceuticals to defend against biological agents. The process will be based upon Genencor's technology for large scale manufacture of monoclonal antibodies in fungal systems which can, theoretically, be used to mass produce a number of newly identified vaccine or therapeutic candidates. The goal is to be able to manufacture 10 million doses of vaccine within 2 months of identifying the biological agent.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-29-2005/0004095483&EDATE=)